Clinical trials: Cardiac Failure
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Heart Failure
Functional Parameters Indicative of Heart Failure.
The present study aims to validate the kinematic analysis obtained by two motion capture instruments for the functional objective assessment of elderly patients with Heart Failire (HF) and to develop a new functional index formed…
- Trial name
- NCT03909919
- Testing
- Standard Care or Usual Clinical Practice
- Where
- Spain
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Malaga
Heart Failure
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic…
- Trial name
- NCT02329834
- Testing
- Fursemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- scPharmaceuticals, Inc.
Cardiovascular Diseases, Coronary Artery Disease
Optimising Secondary Prevention and Quality of Life in Early Cardiac Rehabilitation
The primary aim of this research is to explore the adherence and drop-out from early cardiac rehabilitation (CR), to inform interventions to support patient's adherence to CR and facilitate maintenance.
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome
- Trial name
- OSPREY-CR (NCT04781699)
- Where
- 6 sites in United Kingdom
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Sheffield Hallam University
Heart Failure With Preserved Ejection Fraction
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
This research is being done to better understand the relationship between information collected by wearable devices and clinical measurements in people with heart failure with preserved ejection fraction (HFpEF) and others…
- Trial name
- NCT04998877
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Hypertension, Congestive Heart Failure
Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites
The purpose of this study is to: To determine the rate and routes of excretion of BIA 5-453 and the mass balance in urine and faeces
- Trial name
- NCT03014375
- Testing
- BIA-5-453
- Where
- Switzerland
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Heart Failure
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease.
- Trial name
- COLT-HF (NCT05873881)
- Testing
- Colchicine 0.5 MG, Thiamine Mononitrate 300 mg
- Where
- Canada
- Volunteers
- 2,500 people
- Sponsor
- Hamilton Health Sciences Corporation
Tricuspid Regurgitation, Tricuspid Valve Disease
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve®…
- Trial name
- TRICAV-I (NCT06137807)
- Testing
- TricValve® Transcatheter Bicaval Valve System
- Where
- 36 sites in United States
- Volunteers
- 50 people
- Sponsor
- P+F Products + Features USA Inc.
Heart Failure
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure
- Trial name
- NCT02914665
- Testing
- elamipretide
- Where
- 46 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 308 people
- Sponsor
- Stealth BioTherapeutics Inc.
Cardiopulmonary Exercise Test
Validity of SeismoFit VO2max Estimation in Patients With Heart Failure or Ischemic Heart Disease
Measurement of cardiorespiratory fitness (VO2max) is considered an important tool in risk prediction of cardiovascular disease and overall patient management.
- Trial name
- NCT05520307
- Where
- Denmark
- Volunteers
- 180 people
- Sponsor
- University of Copenhagen
Acute Cardiac Event, Acute Cardiac Failure
Monitoring Patients With Acute Cardiac Disease Using a Wireless, Wearable, Non-invasive Monitor
A prospective observational study in patients admitted with an acute cardiac disease, in which the PPG-based device will be attached to them on admission, for frequent monitoring of their vitals during hospitalization and…
- Conditions
- Acute Cardiac Event, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
- Trial name
- NCT04635371
- Testing
- Non-invasive Monitoring
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Biobeat Technologies Ltd.
Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials.
- Trial name
- EMPA-PRED (NCT06249945)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent
Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment
With the aging of society, the use of cardiac pacing in patients with irreversible bradycardia is increasingly widespread. As early as the 1950s, right ventricular pacing (RVP) began to be used in patients with atrioventricular…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent, Sick Sinus Syndrome, Atrioventricular Block
- Trial name
- NCT05575557
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai 10th People's Hospital
Heart Failure, Atrial Fibrillation
Cardiac Contractility Modulation in Patients With Chronic Heart Failure and the Various Forms of Atrial Fibrillation
Chronic heart failure (CHF) is a global pandemic which affects around 26 million people worldwide and develops in 10% of people over 70 years .
- Conditions
- Heart Failure, Atrial Fibrillation, Left Ventricular Ejection Fraction
- Trial name
- NCT05550792
- Testing
- optimizer smart
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Reduced Ejection Fraction, Heart Failure; With Decompensation
Improving Knowledge in Heart Failure Inpatient With Therapeutic Education
The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure; With Decompensation, Pharmacist-Patient Relations, Medication Adherence
- Trial name
- EDUC-IC (NCT05751772)
- Testing
- Patient therapeutic education
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- University Hospital, Geneva
Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
The primary objective of this study is to Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this…
- Trial name
- DYNAMIC (NCT02744339)
- Testing
- Riociguat
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Vienna
Heart Diseases, Arrhythmia, Cardiac
Evaluation of the LVivo Image Quality Scoring (IQS)
The study includes two parts: Part 1: 100 examinations of patient referred for echo evaluation, containing clips that were acquired from the 4CH apical view were collected retrospectively.
- Conditions
- Heart Diseases, Arrhythmia, Cardiac, Angina Pectoris, Unstable Angina
- Trial name
- NCT05563701
- Where
- Israel
- Volunteers
- 164 people
- Sponsor
- DiA Imaging Analysis Ltd
Congestive Heart Failure
Study of Coronary Artery Disease by Two Types of Angiography
The purpose of this study is to test the ability of a new X-ray technique called CT angiography to identify significant narrowing of the coronary arteries compared to traditional coronary angiogram.
- Trial name
- NCT00273819
- Testing
- CT angiography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Connecticut Healthcare System
Heart Failure, Preserved Ejection Fraction
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure…
- Trial name
- ENRICH-PEF (NCT06350487)
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Samsung Medical Center
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Beta 3 Agonist Treatment in Heart Failure
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart failure.
- Trial name
- Beat-HF (NCT01876433)
- Testing
- Mirabegron
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 70 people
- Sponsor
- Henning Bundgaard